Sotagliflozin: all 60 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Precision T1D Platform - New Therapies for Cardio-Renal ComplicationsNot yet recruitingNCT07594145Phase 2
• Sotagliflozin as Prevention of Anthracycline-Related CardiotoxicityNot yet recruitingNCT07572175Phase 2
• Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationNCT07547878Phase 4
• Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 InhibitorsNot yet recruitingNCT07421518Phase 2
• Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 DiabetesRecruitingNCT06435156Phase 2
• Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic CardiomyopathyRecruitingNCT06433050Early Phase 1
• Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney DiseaseRecruitingNCT06217302Phase 3
• Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxiaNot yet recruitingNCT06147232Phase 2
• Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesRecruitingNCT06082063Phase 3
• Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) PatientsCompletedNCT05562063Phase 4Results posted
• Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)TerminatedNCT03521934Phase 3Results posted
• Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlTerminatedNCT03386344Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminCompletedNCT03351478Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyCompletedNCT03332771Phase 3Results posted
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskTerminatedNCT03315143Phase 3Results posted
• Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart FailureTerminatedNCT03292653Phase 2Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic AgentsCompletedNCT03285594Phase 3Results posted
• Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlCompletedNCT03242252Phase 3Results posted
• A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlCompletedNCT03242018Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With MetforminCompletedNCT03066830Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminCompletedNCT02926950Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic TherapyCompletedNCT02926937Phase 3Results posted
• A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AloneCompletedNCT02531035Phase 3Results posted
• Dose-ranging Study in Patients With Type 1 Diabetes MellitusCompletedNCT02459899Phase 2Results posted
• Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02421510Phase 3Results posted
• Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02384941Phase 3Results posted
• Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1CCompletedNCT02383940Phase 2Results posted
• Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusCompletedNCT01742208Phase 2Results posted
• Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on MetforminCompletedNCT01376557Phase 2Results posted
• Study of LX4211 in Subjects With Type 2 Diabetes MellitusCompletedNCT00962065Phase 2Results posted
• Antithrombotic Activities of Sotagliflozin vs. EmpagliflozinCompletedNCT06618976Phase 4
• A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyActive, not recruitingNCT06481891Phase 3
• Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 DiabetesActive, not recruitingNCT05696366Phase 1/2
• Sotagliflozin Multiple-dose Study in Healthy Chinese SubjectsCompletedNCT03909451Phase 1
• Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female SubjectsCompletedNCT03802487Phase 1
• A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted ConditionsCompletedNCT03776227Phase 1
• Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without SulfonylureaTerminatedNCT03761134Phase 3
• Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and ExerciseTerminatedNCT03760965Phase 3
• Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate HypertensionCompletedNCT03462069Phase 2
• A Drug-Drug Interaction Study Between Sotagliflozin and RamiprilCompletedNCT03414723Phase 1
• A Drug to Drug Interaction Study of Sotagliflozin With HydrochlorothiazideCompletedNCT03387657Phase 1
• Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy SubjectsCompletedNCT03310944Phase 1
• Sotagliflozin Bioequivalence StudyCompletedNCT03211195Phase 1
• A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy SubjectsCompletedNCT03174548Phase 1
• Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female SubjectsCompletedNCT03070678Phase 1
• Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of SotagliflozinCompletedNCT03063580Phase 1
• A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and MetoprololCompletedNCT02940379Phase 1
• Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal FunctionCompletedNCT02647918Phase 1
• Oral Contraceptive DDI StudyStatus unknownNCT02494609Phase 1
• PK Study of Sotagliflozin in Subjects With Hepatic ImpairmentCompletedNCT02471274Phase 1
• Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 TabletsCompletedNCT02373046Phase 1
• DDI Study With Multiple-dose LX4211 and Single Dose RosuvastatinCompletedNCT02300363Phase 1
• Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult SubjectsCompletedNCT01916863Phase 1
• Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy SubjectsCompletedNCT01916850Phase 1
• Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy SubjectsCompletedNCT01913002Phase 1
• Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male SubjectsCompletedNCT01818232Phase 1
• Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal ImpairmentCompletedNCT01555008Phase 1
• A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsCompletedNCT01441232Phase 1
• A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy SubjectsCompletedNCT01292993Phase 1
• Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes MellitusCompletedNCT01188863Phase 1

← Sotagliflozin overview